ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of immunotherapy products for the treatment of allergies, has appointed Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects.
Gerd Zettlmeissl has been independent director of ASIT biotech since 2011 and prior to that he was the CEO of Austrian company Intercell AG, an innovative vaccine company that merged with French company Vivalis in 2013 to create Valneva.